| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| neomycinsulfatpræparat til oftalmisk anvendelse |
Is a |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| neomycinsulfat, opløsning til anvendelse i øre |
Is a |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Framycetin sulfate [systemic] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Framycetin sulfate [eye] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Neomycin sulfate 5 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| neomycinsulfat 0,5 % øjendråber til engangsbrug |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Neomycin sulfate 5 mg/g eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Framycetin sulfate [ear] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| neomycin 0,5 % + hydrocortison 1,5 % øredråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Product containing precisely hydrocortisone acetate 15 milligram/1 gram and neomycin sulfate 5 milligram/1 gram conventional release ear and eye ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| neomycin + hydrocortison 0,5 %/1,5 % øjen-/øredråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Neomycin ear drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Neomycin ear ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Neomycin 0.5% ear drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Framycetin sulfate [skin] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Neomycin 0.5% cream BPC |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Product containing precisely framycetin sulfate 5 milligram/1 milliliter conventional release eye drops (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Product containing precisely framycetin sulfate 5 milligram/1 gram conventional release eye ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| neomycin til topikal anvendelse |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Neomycin 5 mg/g cutaneous ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| hydrocortisonacetat 1,5 % + neomycinsulfat 0,5 % øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| bacitracinzink 400 enheder + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Bacitracin zinc + neomycin sulfate + polymyxin b sulfate 400unt/5mg/10000unt ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| bacitracinzink 500 enheder + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| dexamethason 1 mg + neomycinsulfat 3,5 mg salve |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Dexamethasone sodium phospha + neomycin sulfate 0ns/0ns solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| gramicidin 0,025 mg + neomycinsulfat 1,75 mg + polymyxin B-sulfat 10.000 enheder opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| hydrocortison + neomycinsulfat + polymyxin B-sulfat 10 mg/5 mg/10.000 opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| hydrocortisonacetat 5 mg + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder creme |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| neomycinsulfat + polymyxin B-sulfat + prednisolonacetat 0,35 %/10.000 enheder/0,5 % wt/vol suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
| Product containing framycetin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
neomycin til topikal anvendelse |
Inferred relationship |
Some |
|
FHIR